Plain-English translation of NCT05757219 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , taken as a daily pill, can help prepare the body before receiving CAR-T cell therapy for a type of blood cancer called diffuse large B-cell lymphoma. The research team believes that starting this medication about 4–6 weeks before the CAR-T infusion—especially in patients with high inflammation levels—may improve how well the treatment works and reduce side effects.
CAR-T cell therapy is a powerful cancer treatment, but it can trigger severe inflammatory reactions in the body. This study is testing whether the medication can calm down this inflammation before CAR-T therapy begins, potentially making the treatment safer and more effective.
You likely qualify if…
You likely don't qualify if…
You would start taking the medication daily once your CAR-T cells are being manufactured—about 4–6 weeks before your CAR-T infusion. On the day of your CAR-T therapy (called Day 0), you would receive the infusion, and then continue taking the daily pill for 30 days afterward. During this time, you will have regular clinic visits and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Incyte Corporation
Enrollment target
~27 participants
Started
May 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.